STEEPER
1.9.2021 13:09:04 CEST | Business Wire | Press release
In their centenary year Steeper Group, a world leading manufacturer of prosthetic devices, launch their latest myoelectric system. The full limb build is designed to offer patients and clinicians across the globe a durable, high-capacity upper limb system at an affordable cost, which harnesses the power of popular myoelectric technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005522/en/
Designed for the everyday, the Steeper Myoelectric System includes the new Myo Kinisi hand which provides an easy to control, high-speed grasp alongside a strong grip force to carry out activities of daily living with ease, with the added benefit of an Auto-Grip function allowing users a more secure grip on difficult to hold objects. The hand is complemented by advanced myoelectrodes for increased accuracy and gain control, and is powered by the all new high-capacity S-Charge System which features a 3500mAh internal battery, making it one of the most powerful available. The prosthesis is finished by the ‘Elegance Plus’ cosmetic glove, designed specifically to complement the Myo Kinisi.
Paul Steeper, CEO of Steeper Group and SteeperUSA commented “a new myoelectric system is something our customers have desired for some time. We’ve used our innovative knowledge of upper limb prostheses to deliver an evolution to a myoelectric system; using the latest advancements in product design, super capacitor technology and modern materials such as titanium for increased strength.”
Patients will enjoy the enhanced cosmesis given by the Elegance Plus silicone glove which has been designed to work in harmony with the Myo Kinisi. An internal reinforced mesh layer increases durability for even high activity users, and improved realism to the skin appearance is achieved with enhancement on the knuckles, joints and nail finish; the Elegance Plus Glove is available in 19 TrueFinishTM shades.
Clinicians can program the Myo Kinisi to meet exacting patient preferences with a choice of five modes and fine adjustments to control parameters can be made via the Steeper Configuration Device, a simple three button operation programming hub with an easy-to-read screen.
Paul Steeper concluded “the Steeper Myoelectric System will offer both clinicians and users a greater choice of durable, reliable and easy to use devices. The Myo Kinisi offers superb grip strength via trusted technology and the Elegance Plus Glove is sure appeal to a wide range of users with its enhanced finish and skin-like texture; couple that with our very latest myoelectrodes and increased capacity S-Charge battery system and users will instantly benefit from these innovations. Patient trials have proved successful with users commenting on the increased control the Myo Kinisi offers whilst using a control strategy they are already familiar with; meaning the hand is easily and readily usable.”
ENDS
Notes to editors:
Steeper Group trade as SteeperUSA within the United States and Canada.
For more information on the Steeper Myoelectric System or any of our upper limb prosthetic products, please visit www.steepergroup.com or www.steeperusa.com .
Image caption: The Steeper Upper Limb Build offers a secure grip, an enhanced cosmetic appearance and is powered by one of the most powerful battery systems on the market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005522/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom